



PROGRAM BOOK

8-9 NOVEMBER 2024

MAANI HOTEL, MUSCAT, OMAN

ORGANIZED BY

الرابطة العمانية
لطب المخ
والاعصاب



Oman
Neurology
Society



رابطة الصرع العمانية
Oman League Against Epilepsy



جمعية الصرع العمانية
Oman Epilepsy Society

IN COLLABORATION WITH



سلطنة عُمان
وزارة الصحة
SULTANATE OF OMAN
MINISTRY OF HEALTH



جامعة السلطان قابوس
@Sultan Qaboos University



Sultanate Of Oman
University Medical City

ENDORSED BY



ACCREDITED BY



الجمعية العامة للتخصصات الطبية
OMAN MEDICAL SPECIALTY BOARD

WELCOME MESSAGE

Dr. Abdullah Al-Asmi, MD, FRCP(C)
ONC 2024 Chairman



Dear Esteemed Colleagues,

On behalf of the Oman Neurology Society (ONS) and Oman Epilepsy Society (OES), it is with great excitement that I extend a warm welcome to you all to the much-anticipated 4th Oman Neurology Conference (ONC 2024)! Mark your calendars for November 8th-9th, 2024, as we gather in the vibrant city of Muscat, Sultanate of Oman, for an extraordinary event dedicated to advancing the field of neurology.

This year's conference will offer a rich scientific program encompassing a diverse array of subspecialties within Neurology. From cutting-edge diagnostic techniques to revolutionary treatment modalities, ONC 2024 will showcase the forefront of Neurological innovation and excellence.

In addition to the stimulating academic program, attendees will have the opportunity to immerse themselves in the captivating charm of Muscat, renowned for its stunning landscapes, rich cultural heritage, and warm hospitality.

Don't miss out on this exceptional opportunity to be part of this scientific conference. Register now to secure your place at ONC 2024.

We eagerly anticipate your participation and look forward to welcoming you to Muscat for an unforgettable conference experience!



PROGRAM




PROGRAM

SCIENTIFIC PROGRAM

DAY 1, FRIDAY- 8 NOVEMBER 2024

07:00 – 09:00	REGISTRATION	
TIME	TOPIC	SPEAKER
08:00 - 09:10	Session 1: Emerging Advances in Neurology	Moderators: Prof. Arunodaya Gujjar & Prof. Amna Al Futaisi
08:00 - 08:20	Venous Sinus Stenting in IIH	Dr. Ali Al Balushi (Oman)
08:20 - 08:40	Alzheimer Disease- Disease Modifying Therapies	Dr. Haythum O Tayeb (KSA)
08:40 - 09:00	Artificial intelligence in Neurology (Virtual)	Dr. Benjamin Kummer (USA)
09:00 - 09:10	Q & A	All speakers
09:10 – 09:40	Pfizer Symposium: How can we harness Rimegepant in clinical practice today and into the future?	Moderator: Dr Ahmed Al Qassabi Speaker: Dr Taoufik Alsaadi (UAE)
09:40 – 09:55	Opening Ceremony	
09:55 – 10:20	Coffee break	
10:20 – 10:40	Novartis Symposium: Pioneering Precision with Kesimpta- The first and only self administered anti-CD20 therapy in MS	Moderator: Dr Abdullah Al Asmi Speaker: Dr Iman Al Lawati (Oman)





PROGRAM

SCIENTIFIC PROGRAM

DAY 1, FRIDAY- 8 NOVEMBER 2024

TIME	TOPIC	SPEAKER
10:40 - 12:10	Session 2: Epilepsy	Moderators: Dr. Fatma Abdulla, Dr. Said Al Mawali & Dr. Ahmed Mansy
10:40-11:00	Management of multifocal epilepsy	Dr. Sulaiman Al Hatmi (Oman)
11:00 - 11:20	Surgical management of epilepsy	Dr. Faisal Al Otaibi (KSA)
11:20 - 11:40	Benign epilepsy syndromes	Dr. Raidah Al Baradie (KSA)
11:40 - 12:00	Vitamin responsive epilepsies	Prof. Amna Al Futaisi (Oman)
12:00 - 12:10	Q&A	All speakers
12:10 - 13:50	Friday Prayer and Lunch break /Poster sessions	
13:50-14:10	Novartis Symposium: Signs of SMA	Speaker: Dr Nabil Al Macki (Oman)
14:10-14:30	AstraZeneca Symposium: Focus on timing on Myasthenia Gravis Management	Moderator: Dr. Abdullah Al-Salti Speaker: Dr. Areej Bushnag (KSA)
14:30 - 16:00	Session 3: Neuroimmunology & Neuroinflammatory diseases	Moderators: Dr. Abdullah Al Asmi & Dr. Jaber Al Khabouri
14:30 - 14:50	Pregnancy & lactation in MS	Dr. Iman Al Lawati (Oman)
14:50 - 15:10	Pediatric neurodemyelinating syndromes	Dr. Nabil Al Macki (Oman)




PROGRAM

SCIENTIFIC PROGRAM

DAY 1, FRIDAY- 8 NOVEMBER 2024

TIME	TOPIC	SPEAKER
15:10 - 15:30	Modern therapies of multiple sclerosis	Dr. Yasser Al Malik (KSA)
15:30 - 15:50	Updates on NMOSD & MOGAD (Virtual)	Dr. Dina Dababneh (USA)
15:50 - 16:00	Q&A	All speakers
16:00 - 16:20	Coffee break	
16:20 - 17:30	Session 4: Cognitive & Behavioral Neurology	Moderators: Dr. Haythum O Tayeb and Dr. Khaleel Al Shaikhli
16:20 - 16:40	Autoimmune Encephalitis Update (Virtual)	Dr. Sarosh Irani (USA)
16:40 - 17:00	Rapidly progressive dementias	Dr. Ammar Al Obaidy (Oman)
17:00- 17:20	Management of behavioral symptoms in dementia	Dr. Hamed Al Sinawi (Oman)
17:20 - 17:30	Q&A	All speakers
WORKSHOPS		
16:30 - 17:30	Room 1: Seizure recognition and semiology	Dr. Haifa Al Abri and Dr. Wafaa Al Shehhi (Oman)
	Room 2: Neuro-ophthalmology cases	Dr. Buthaina Sabt (Oman)



PROGRAM

SCIENTIFIC PROGRAM



DAY 2, SATURDAY- 9 NOVEMBER 2024

07:00 – 08:00

REGISTRATION

WORKSHOPS

TIME

TOPIC

SPEAKER

07:30 - 08:30

Room 1: Myelopathy cases

Dr. Iman Al Lawati &
Dr. Khalsa Al Ramadhani (Oman)

Room 2: Stroke cases

Dr. Achint Krishna & Dr. Ali Al Balushi
(Oman)

08:00 - 09:30

Session 5: Headaches

Moderators: Dr. Abdullah Al Asmi &
Dr. Abu Baker Madani

08:00 - 08:20

Headaches in children

Dr. Areeba Wasim (Oman)

08:20 - 08:40

Updates on giant cell arteritis
management

Dr. Tariq Al Araimi (Oman)

08:40 - 09:00

Medication-overuse headaches

Dr. Alessandro Terruzi (UAE)

09:00 - 09:20

Migraine modern therapies

Dr. Abdulrazaq Al Bilali (KSA)

09:20 - 09:30

Q & A

All speakers

09:30 – 09:50

Pfizer Symposium: A single medication to
both treat and prevent migraine- What is
the evidence?

Moderator: Dr. Ali Al Balushi
Speaker: Dr. Deeb Kayed (UAE)



PROGRAM

SCIENTIFIC PROGRAM

DAY 2, SATURDAY- 9 NOVEMBER 2024

TIME	TOPIC	SPEAKER
09:50 – 10:20	Coffee break	
10:20 – 10:40	Merck Symposium: Optimizing Treatment Approach for RRMS Patients	Moderator: Dr Abdullah Al Asmi Speaker: Dr Iman Lawati (Oman)
10:40 - 12:30	Session 6: Neuromuscular Disorders	Moderators: Dr. Abdullah Al Salti & Dr. Ahmed Sameer
10:40 - 11:00	Autonomic neuropathy and postural orthostatic tachycardia syndrome	Dr. Mossaed Al Yahya (KSA)
11:00 - 11:20	Neuromuscular crisis	Dr. Abu Baker Madani (UAE)
11:20 - 11:40	Approach to floppy infant	Dr. Fatema Al Amrani (Oman)
11:40 - 12:00	Modern therapies of myasthenia gravis	Dr. Mossaed Al Yahya (KSA)
12:00 - 12:10	Q&A	All speakers
12:10 – 12:30	Biogen Symposium: When Improvement is Possible in Teens and Adults with SMA.	Speaker: Dr. Areej Bushnag (KSA)
12:30 – 13:40	Lunch Break/ Poster Presentations	
13:40 – 14:00	Roche Symposium: Ocrevus- A decade of preventing disability	Moderator: Dr Abdullah Al Asmi Speaker: Dr Raed Al Roughani (Kuwait)
14:00-15:30	Session 7: Vascular Neurology & Neurocritical Care	Moderators: Dr. Ali Al Balushi & Dr. Suhail Al Rukun

PROGRAM

SCIENTIFIC PROGRAM



DAY 2, SATURDAY- 9 NOVEMBER 2024

TIME	TOPIC	SPEAKER
14:00 - 14:20	Stroke in young adults and children	Dr. Ashraf El Mitwalli (Oman)
14:20 - 14:40	Approach to ischemic strokes due to multiple mechanisms	Prof. Arunodaya Gujjar (Oman)
14:40 - 15:00	Current treatment of subarachnoid hemorrhage	Dr. Ahmed Al Azri (Oman)
15:00 - 15:20	Management of raised ICP	Dr. Caline El Jadam (UAE)
15:20 - 15:30	Q & A	All speakers
15:30 - 15:50	Awards and Recognitions	
15:50-16:10	Coffee break	
16:10 - 17:20	Session 8: Movements Disorders	Moderators: Dr. Ahmed Al Qassabi and Dr. Jaber Al Khabouri
16:10 - 16:30	Approach to shaky hands	Dr. Mahmood Al Hinai (Oman)
16:30 - 16:50	DBS for movements disorders (Virtual)	Dr. Erik Krause (USA)
16:50 -17:10	Phenomenology of Movements Disorders in Children	Dr. Wejdan Hakami (KSA)
17:10 - 17:20	Q&A	All speakers
17:20 - 17:30	Closing Remarks	

The background features a solid red field with abstract, wavy shapes in shades of red and green at the top. The word "ABSTRACTS" is centered in white, bold, uppercase letters.

ABSTRACTS

SCIENTIFIC TALKS

DAY 1, FRIDAY- 8 NOVEMBER 2024

Dr. Ali Al Balushi

MD

Dr. Ali K. Al Balushi is a consultant, vascular & interventional neurologist and currently head of department of neurology and stroke unit at Khoula Hospital, Oman. He obtained his medical degree from Sultan Qaboos University and completed neurology residency at St Louis University School of Medicine. He then completed fellowship in vascular neurology from Icahn School of Medicine at Mount Sinai and another fellowship in endovascular neurosurgery from Weill Cornell School of Medicine. He is board certified in Neurology and Vascular Neurology by the American Board of Psychiatry and Neurology. He serves as the associate program director for Oman Medical Specialty Board Neurology residency program. Dr. Ali is the Chairman of the Scientific Committee of the 4th Oman Neurology Conference.



“ Venous Sinus Stenting in IIH: Dr. Ali Al Balushi

Idiopathic intracranial hypertension (IIH) typically affects overweight women of childbearing age. It results from increased intracranial pressure in absence of secondary causes. The major complications are permanent vision loss and disabling headaches. Medical treatment consists of weight loss and acetazolamide. Surgical treatment is indicated in patients with progressive or fulminant vision loss and in patients unresponsive to or intolerant of medical management. Optic nerve sheath fenestration and cerebrospinal fluid shunting are the main traditional surgical options. Recently however, stenosis of bilateral or dominant transverse-sigmoid venous sinus junction has been implicated in the pathogenesis of some patients with IIH and, consequently, stenting has emerged as a durable alternative therapy with good efficacy and safety outcomes when well-indicated. In this lecture, a brief discussion of the rationale and evidence supporting venous sinus stenting in IIH patients will be presented.

Dr. Haythum O Tayeb

MD FRCP Canada

Haythum O Tayeb is a Harvard-trained professor of neurology and the president of the Saudi Chapter of Behavioral Neurology. He is the chief of the institute of Mind and Brain Studies at King Abdulaziz University.



“ Alzheimer disease modifying therapies: Dr. Haythum O Tayeb

There have been recent revolutionary developments in the field of Alzheimer disease and cognitive aging. There are new disease biomarkers and new disease modifying treatments. In addition, there is a new emphasis on brain health as a major clinical target endorsed by major neurological societies worldwide. In this talk, Dr. Tayeb discusses these updates and reviews these developments on how they have transformed the way we evaluate patients with Alzheimer disease and cognitive impairment.

SCIENTIFIC TALKS

DAY 1, FRIDAY- 8 NOVEMBER 2024

Dr. Benjamin Kummer

MD

Dr. Benjamin Kummer is a triple-board certified vascular neurologist and clinical informaticist at the Icahn School of Medicine at Mount Sinai, where he serves as Associate Professor in Neurology and Artificial Intelligence and Human Health, and at Mount Sinai Health System (MSHS) as Director of Clinical Informatics in Neurology. Dr. Kummer has expertise in using informatics to enhance patient care in neurology, by building solutions in Epic and other clinical systems, with a focus on stroke. He is the Director of one of the first neuro-informatics research institutes (the Clinical Neuro-informatics Center at Mount Sinai) in the US.




Artificial intelligence in Neurology: Dr. Benjamin Kummer

Artificial intelligence (AI) is transforming neurology by offering advanced tools for diagnosis, prognosis, and treatment. This presentation will provide an overview of AI in neurology to establish a clear framework for understanding the potential of these technologies in neurological disorders. We will first discuss basic definitions in the AI lexicon including machine learning, deep learning, natural language processing, and large-language models. We will then briefly explore the major clinical areas where AI is making an impact divided into three broad areas: treatment, prognosis, and diagnosis. We will then discuss the challenges facing AI and potentially impacting adoption: data quality issues, limited generalizability of models, biases in algorithms, regulatory hurdles, and ethical concerns. We will also highlight the need for interdisciplinary collaboration to ensure AI technologies are developed and deployed responsibly in clinical neurology.

Dr. Sulaiman Al Hatmi

MD, MRCP (Neurology) / OMSB, RCPI (General Neurology), RCPI (Epilepsy)

Dr Sulaiman is currently working as Sr Consultant Neurologist and epileptologist in the Medical City for Military and Security Services. After completing Clinical Epilepsy Fellowship at Beaumont (Level 4 NAEC , National Association of Epilepsy Centers) Dublin , Ireland . Dr Sulaiman is a specialist epilepsy disorders Neurologist. His practice focusses exclusively on general neurology and the management of refractory cases of epilepsy. He has experience in the provision of all medical and surgical therapies for epilepsy including drug resistance multifocal epilepsy.



Management of multifocal epilepsy: Dr. Sulaiman Al Hatmi

Patients with medically refractory focal epilepsy due to multiple ictal onset zones can be difficult to treat surgically. These subgroup of drug refractory epilepsy are among the most difficult epileptic disorders to manage since they are often refractory to medical therapy and not treatable by resective epilepsy surgery , historically were thought to be poor surgical candidates. If ictal onset seizure is difficult to localize by standard video electroencephalography (EEG) monitoring, or if bilateral or eloquent area ictal onset is suspected, the patients move on to have invasive monitoring studies including stereo electroencephalography (sEEG) or subdural grids (SDG) to better delineate the ictal onset zone(s). Depending upon the location of the onset zone, subsequent resection, neurostimulation, or laser ablation might be performed or even a combination of these surgical modalities. The presentation high light briefly a new therapeutic strategies for these patients based on latest available surgical techniques .

SCIENTIFIC TALKS

DAY 1, FRIDAY- 8 NOVEMBER 2024



Prof. Faisal Al Otaibi

MD, FACS

Dr. Faisal Alotaibi is a Professor of Neurological surgery at King Faisal Specialist & Research Centre , Alfaisal University in Riyadh, Saudi Arabia. He obtained his neurosurgical training in epilepsy surgery at the Western University in Canada and Functional stereotactic neurosurgery at the London Health Sciences Centre in Canada and a Fellow of the American College of Surgeons. Currently, Dr. Alotaibi is a founding board member of the International Epilepsy Surgery Society IESS and the president of Saudi Epilepsy Society. He is former president of the Gulf League Against Epilepsy, GLAE. He is an editor and reviewer in local and international journals.




Epilepsy Surgery Advancements-The New in The Field: Prof. Faisal Al Otaibi

Epilepsy surgery is supported by technological advancement that has evolved over the last two decades. Wilder Penfield and colleagues at the Montreal Neurological Institute pioneered using epilepsy surgery patients to perform basic neuroscience research. Here, we shed light on the most advanced techniques and technology for epilepsy surgery and other neurosurgical procedures. Brain cortical mapping was started essentially in that era by direct cortical electrical mapping of different brain functions. Brain function mapping has progressed beyond electrical stimulation to utilizing the most advanced techniques and technology. Functional imaging has contributed to a better understanding different brain functions and the epilepsy network exploration. On the other hand, deep brain recording has resulted in more advancement in the field of brain connectivity.

Dr. Raidah Al Baradie

MD, ABMS, MSHA

Dr. Raidah Saleem Al-Baradie is a Consultant Pediatric Neurologist & Epileptologist and the Director of Comprehensive Epilepsy Program. She is the Neurology EHC1 Lead at King Fahad Specialist Hospital, Department of Neuroscience.



Benign Childhood Epilepsy: Dr. Raidah Al Baradie

Epilepsy is defined as 2 or more unprovoked seizures. The various types of epilepsy differ in many aspects, including (1) age of onset, (2) semiology, (3) EEG findings, and (4) outcome. In 1987, Freeman et al reported that most children with generalized tonic-clonic seizures have a benign developmental disorder that reduces their seizure threshold and will be outgrown. This disorder has been termed benign childhood epilepsy and is thought to be secondary to central nervous system (CNS) immaturity. In this presentation, the term benign epilepsy is used to refer to a group of pediatric epileptic disorders in which remission and lack of significant neurologic sequelae are expected in the vast majority of patients. These disorders are idiopathic, occur in otherwise healthy children, and have (with rare exceptions) a strong genetic component. They include generalized epilepsies and partial epilepsies. These epilepsies are presented according to the age of onset, starting from the neonatal period.

SCIENTIFIC TALKS

DAY 1, FRIDAY- 8 NOVEMBER 2024

Prof. Amna Al Futaisi

MD, FRCPC, FRCPCH

Prof. Amna Mohammed Al Futaisi is a Professor and Senior Consultant at the Sultan Qaboos University- College of Medicine and Health Sciences (SQU-COMHS) and University Medical City-Sultan Qaboos University Hospital (UMC SQUH) specializing in Pediatric Neurology and Pediatric Neuro-electrophysiology and Epilepsy. She is the President of the Oman League Against Epilepsy, Chairperson of Pediatric Neurology Program-Arab Board, Member of the pediatric council in the Arab Board of Medical Specialization, Founding member of GCC Pediatric Neurology Society, member of the Oman National Delegate Asian Oceanian Child Neurology Association and a board member of the Oman Neurology Society. Prof. Amna has an interest in clinical research in pediatric neurology, neurogenetics, cerebral palsy, and epilepsy, with many publications in peer-reviewed journals.



Vitamin responsive epilepsies: Prof. Amna Al Futaisi

Vitamin-responsive epilepsies are a group of rare, treatable seizure disorders that respond to specific vitamin supplementation, often with significant clinical improvement. These conditions can present with diverse seizure types, ranging from early infantile epileptic encephalopathies to more subtle, treatment resistant epilepsy. The identification of these conditions is crucial, as early recognition and treatment can prevent neurological deterioration and improve quality of life. This presentation will focus on key vitamin deficiencies linked to epilepsy, including pyridoxine (vitamin B6), folic acid, and biotin, with an emphasis on the pathophysiology, clinical presentations, diagnostic approaches, and therapeutic interventions.

Dr. Iman Al Lawati

MD, MRCP

Dr. Iman Al Lawati is a Consultant neurologist and Multiple sclerosis (MS) specialist at Khoula Hospital, where she oversees the MS care unit. She has authored several publications in her field and has participated as an investigator in numerous clinical trials for MS in the UK. Her primary research interest focuses on pregnancy and lactation among MS patients.



Navigating Pregnancy and Lactation in Multiple Sclerosis-Challenges and Strategies:

Dr. Iman Al Lawati

This presentation will explore the unique challenges faced by women with multiple sclerosis (MS) during pregnancy and lactation. We will discuss the latest research on disease management, medication safety, and the impact of hormonal changes on MS progression. Attendees will gain insights into best practices for supporting maternal and infant health, addressing patient concerns, and optimizing care strategies.

SCIENTIFIC TALKS

DAY 1, FRIDAY- 8 NOVEMBER 2024

Dr. Nabil Al Macki

MRCPCH, FRCP-C

Dr. Nabil Al Macki is a Senior consultant Pediatric neurologist. He completed Pediatric neurology training at McGill University 2004- 2009 and Fellowship in pediatric neurophysiology. He has special interests in intractable epilepsies, neurogenetic and neurometabolic disorders. Dr. Nabil is a member in an international commission on medical therapy from the international League Against Epilepsy (ILAE) Task force for dietary therapy.



Pediatric neuro-demyelinating syndromes: Dr. Nabil Al Macki

Neuro- immune disorders of the central nervous system are a rapidly expanding field. There are several childhood demyelinating disorders based on clinical presentations, radiological features and the presence of autoantibodies. Our understanding of the pathobiology, classification, treatment, and prognosis of acquired demyelinating disorders in children is rapidly growing.

Dr. Yasser Al Malik

MD, FRCPC

Dr. Yaser Al Malik is an Associate Professor of Neurology and Associate Dean of Academic affairs at College of Medicine, King Saud bin Abdulaziz University for Health sciences, Riyadh, Saudi Arabia. He is also a Consultant Neurologist and head of Multiple sclerosis/Neuroimmunology division, Neurology department at King Abdulaziz medical city in Riyadh. He serves as the head of MS Chapter at Saudi Neurology Society. Dr. Al Malik completed his residency training in adult neurology at University of Calgary, Canada in 2014. He has 2 Fellowships: in Multiple Sclerosis and Neuroimmunology, and in Clinical Neurophysiology (2016-2017). He has a Master's degree in Medical Education (2021).



Modern therapies of Multiple sclerosis: Dr. Yasser Al Malik

This presentation explores the latest advancements in the treatment of Multiple Sclerosis (MS), highlighting the evolution of therapeutic strategies over recent years. We will examine the spectrum of modern disease modifying therapies (DMTs), emphasizing their mechanisms of action, efficacy, and safety profiles. Additionally, we will discuss the role of personalized medicine in MS management, including the integration of biomarkers and patient-specific factors in treatment decisions. The presentation will also address emerging therapies and future directions in MS research, aiming to improve patient outcomes and quality of life.

SCIENTIFIC TALKS

DAY 1, FRIDAY- 8 NOVEMBER 2024

Dr. Dina Dababneh

MD

Dr. Dina Dababneh is an Assistant Professor of Neurology at Columbia Irving Medical Center in New York. Dr. Dababneh has a sub-specialization in Multiple Sclerosis. Her clinical practice includes all types of neurological disorders with expertise in Multiple Sclerosis. Dr. Dababneh won multiple awards for outstanding professional and research skills.



“ Updates on MOGAD disease: Dr. Dina Dababneh

In this presentation, the historical perspective of Myelin Oligodendrocyte Glycoprotein Associated Disorders will be discussed, in addition, will discuss clinical phenotypes and approach to differentiating MOGAD from other demyelinating disorders, approach to diagnosis and updates on treatment.

”

Dr. Sarosh Irani

BMBCh MA (Oxon) Dphil FRCP FEAN

Prof. Sarosh Irani is a clinician-scientist who established the Oxford Autoimmune Neurology Group and is now Professor of Neurology and Neurosciences at the Mayo Clinic, Florida. His contributions to the field have been the discovery of LGI1 and CASPR2 antibodies, their related phenotypes in particular faciobrachial dystonic seizures, clinical and serological descriptions of other autoimmune encephalitis and NMOSD patients, and HLA associations. Dr. Sarosh trained at and completed his PhD in Clinical Neurology at Oxford University (DPhil) and, subsequently, residency training in neurology in Oxford, followed by a Fulbright Fellowship in multiple sclerosis and autoimmune neurology in UCSF, USA. He has extensive experience in diagnosing and managing a variety of autoimmune neurological conditions. He has published & >200 peer-reviewed publications and is Associate Editor at the journal Brain.



“ Autoimmune Encephalitis Update: Dr. Sarosh Irani

Autoimmune encephalitis defines brain inflammation caused by a misdirected immune response against self-antigens expressed in the central nervous system. It comprises a heterogeneous group of disorders that are at least as common as infectious causes of encephalitis. The rapid and ongoing expansion of this field has been driven by the identification of several pathogenic autoantibodies that cause polysymptomatic neurological and neuropsychiatric diseases. These conditions often show highly distinctive cognitive, seizure and movement disorder phenotypes, making them clinically recognizable. Their early identification and treatment improve patient outcomes and may aid rapid diagnosis of an underlying associated tumour. Here we summarize the phenotypes, investigations and outcomes of most common forms of AE – in particular LGI1 and NMDAR antibody associated syndromes

”

SCIENTIFIC TALKS

DAY 1, FRIDAY- 8 NOVEMBER 2024

Dr. Ammar Al Obaidy

MD, FIBMS(Neuro I.), MRCP(UK), FRCP(Glasg)

Dr. Ammar Alobaidy is a Behavioral Neurologist at Sultan Qaboos University Hospital in Muscat, Oman. He completed the Iraqi Board of Neurology in 2006 and Behavioral Neurology Fellowship in 2012, from University of Toronto, Canada. He was awarded the Membership of the Royal Colleges of Physicians of UK in 2015 and the Fellowship of the Royal College of Physicians and Surgeons of Glasgow in 2017. He established the Memory Clinic in 2013, for the first time in Oman. He has many publications and international participations. His developed the "Consortium to Establish a Registry for Alzheimer's Disease (CERAD) - Arabic Version", and working on adding a novel executive and visuospatial functions assessment tool to CERAD Arabic version, including a Functional MRI brain mapping.



Rapidly progressive dementias: Dr. Ammar Al Obaidy

Rapidly progressive dementias (RPDs) are a group of heterogeneous disorders that include immune-mediated, infectious and metabolic encephalopathies, as well as prion diseases and atypical rapid presentations of particular neurodegenerative disorders, namely Lewy Body disease and early onset Alzheimer disease, among others. Awareness of possible RPD aetiologies, syndromes and diagnostic work-up protocols will help clinicians to establish an early, accurate diagnosis, thereby reducing morbidity and mortality, especially in immune-mediated and other potentially reversible dementias. To identify treatable causes of RPD, the approach for diagnostic work-up must include MRI and analyses of blood and cerebrospinal fluid, and further diagnostics might be indicated in unclear cases. Therapeutic options for many non neurodegenerative causes of RPD are already available; disease-modifying therapies for neurodegenerative RPDs are an important focus of current research and could become a treatment option in the near future.

Dr. Hamed Al Sinawi

MD, FRCPsych

Dr. Hamed AL Sinawi is Senior consultant Psychiatrist and the Dean of department of Behavioral Medicine, Sultan Qaboos University. He is the founder and Chairman of Oman's Alzheimer's Society and a member of the national bioethics committee. He specializes in Geriatric Psychiatry and became a fellow of the Royal college of Psychiatrist, UK in 2011. His special interest is in cognitive impairment, mood disorder and medical education.



Management of behavioral symptoms in dementia: Dr. Hamed Al Sinawi

Behavioral symptoms in dementia often pose challenges in diagnosis and management and also contribute to caregivers stress and burnout. This presentation will discuss risk factors or behavioral changes, common clinical features, how to detect them and what are the evidence-based interventions that can work. We will discuss both pharmacological and behavioural interventions and use case studies to illustrate the different approaches. Care givers education is key in managing behavioural disorders in dementia as well as caregivers emotional and psychological support as both are shown to reduce caregivers' stress.

SCIENTIFIC TALKS

DAY 2, SATURDAY- 9 NOVEMBER 2024

Dr. Areeba Wasim

MBBS, FCPS Pediatrics, FCPS Pediatric Neurology, MRCPCH UK

Dr Areeba Wasim is a Specialist Pediatric Neurologist currently working in Sultan Qaboos University Hospital Muscat, Oman. She is a graduate of King Edward Medical University Lahore, Pakistan and completed her Pediatric Residency from Mayo Hospital affiliated with King Edward Medical university Lahore Pakistan. Following her passion in Child Neurology, she completed her fellowship in Child Neurology from University of Child Health Sciences and Children Hospital (UCHS) Lahore, Pakistan followed by post-fellowship clinical and research. Her areas of special interest are Childhood Headache and Stroke, Developmental and Epileptic Encephalopathy, Neurogenetics and Neuroimmunology.



Headaches in children: Dr. Areeba Wasim

Headache is one of the common causes of missed school days and one of the most common neurological disease-causing morbidity in children. Migraine is one of the most frequently encountered primary headache disorders affecting nearly 5-40% of the pediatric population with no gender predilection before puberty yet there are other secondary causes of headache to ponder. Identification of red flags in headache via structured systemic approach is mainstay to exclude life threatening and progressive CNS emergencies. In conclusion, Childhood Headache is a worldwide health issue distressing the quality of life; implementation and execution of strategies (Felt Need , Observed Need) to properly manage childhood headaches can alter the lifelong outcome of these children.

Dr. Tariq Al Aرامي

MD. ABIM, FRCPC, MHPE

Dr. Tariq Al Aرامي is a Consultant Rheumatologist, internist and educator at the Royal Hospital in Oman. He is the former Vice President of OSR and currently a board member at Oman Society of Rheumatology (OSR). Trained at the University of Toronto in Internal Medicine and Rheumatology. Dual board certification in Rheumatology and Internal medicine by The Royal College of Physicians and Surgeons of Canada(RCPSC) and the American Board of Internal Medicine(ABIM). He currently also holds a Master's Degree in Health Professions Education (MHPE).



Updates on giant cell arteritis management: Dr. Tariq Al Aرامي

Giant Cell Arteritis (GCA) is a chronic vasculitis primarily affecting large and medium-sized arteries, with significant morbidity if not promptly diagnosed and managed. This lecture will provide an update on the latest advancements in GCA management, focusing on three key areas but mainly pharmacological treatment and highlighting briefly updates in GCA classification criteria and long-term monitoring strategies. The discussion will cover new treatment modalities, in particular the use of corticosteroids and emerging biological/sDMARDs therapies tailored to improve patient outcomes and minimize side effects. Additionally, we will highlight briefly strategies for monitoring disease activity, managing relapses, and addressing long-term patient care. This session aims to equip participants with the knowledge needed to implement evidence-based up to date practices in the management of GCA.

SCIENTIFIC TALKS

DAY 2, SATURDAY- 9 NOVEMBER 2024

Dr. Alessandro Terruzi

MD, OMCEOB Italy

Dr. Terruzi is currently the Head of the Neurology Department at Mediclinic City Hospital and the Clinical Lead and Head of the Mediclinic Comprehensive Stroke Center at City Hospital in Dubai (UAE). Dr Terruzi trained at the University of Medicine and Surgery of Milan Bicocca in Italy, where he received Master's Degree in Cerebrovascular Diseases. He worked as a stroke neurologist at the Neuroscience Department of Manzoni Hospital. He moved to Dubai in 2017 as a Consultant Neurologist. Since 2019, he is an Adjunct Clinical Associate Professor at Mohamed Bin Rashid University, Dubai. Dr.Terruzi's primary interests are diagnosing and treating headaches and cerebrovascular disorders.



Medication overuse headaches: Dr. Alessandro Terruzi

Medication-overuse headache (MOH) is defined as a headache happening on ≥ 15 days a month and overusing one specific type of acute attack medication consecutively for over three months.

It is a far more prevalent condition than expected, with a prevalence ranging from 0.5 to 7.2% in the general population but up to 50% among chronic headache patients in tertiary headache centres. It is one of the most common causes of chronic daily headaches. Pathophysiology is not entirely understood, and proper management still needs to be universally agreed upon, with different protocols to be reviewed. However, ultimately, MOH management cannot be pharmacological only. It requires a multifaceted and patient-centred approach that involves patient education, behavioural interventions, withdrawal of overused medication, and initiation of preventative medication.

Dr. Abdulrazaq Al Bilali

MBBS, FRCPC, MSc, MHA

Dr. Abdulrazaq Al Bilali is a Consultant Neurologist and Headache Specialist at King Saud University Medical City, Riyadh. He is an Assistant Professor of Medicine at King Saud University, Riyadh and Head of the Saudi Headache Chapter. He did his Neurology residency training and Headache fellowship at the University of British Columbia, Vancouver, Canada



Migraine - Modern therapies: Dr. Abdulrazaq Al Bilali

Successful preventive treatment of migraine reduces disease burden and improves quality of life. Many pharmacologic and nonpharmacologic treatment options are available for the prevention of migraine, including newer therapies aimed at the CGRP pathway as well as older treatments with good evidence for efficacy. Multiple treatment trials may be required to find the best preventive for an individual patient.

SCIENTIFIC TALKS

DAY 2, SATURDAY- 9 NOVEMBER 2024

Dr. Mossaed Al Yahya

MD

Dr. Mossaed Al Yahya is a consultant neurologist, neuromuscular and neurooncology specialist at King Faisal Specialist Hospital and Research Center. He obtained his MD degree from King Saud University in the Kingdom of Saudi Arabia in 2013 following which he completed neurology residency and neuromuscular fellowship programs at Case Western Reserve University in Cleveland. He then completed another fellowship in Neuro-oncology at the University of Virginia.



“ Autonomic neuropathy and postural orthostatic tachycardia syndrome: ”

Dr. Mossaed Al Yahya

Autonomic neuropathies represent a group of disorders that affect the autonomic nervous system: either sympathetic or parasympathetic neurons or both. They can be acquired or hereditary. When occurring in isolation, the diagnosis can be challenging. Postural orthostatic tachycardia syndrome results from dysregulation of the autonomic system and typically affects young women. In this lecture, a brief overview of autonomic neuropathies and postural orthostatic tachycardia syndrome will be discussed.

”

Dr. Abu Baker Madani

MD. FRCP Canada

Dr. Abubaker Al Madani is a Consultant and Head of Neurology Department at the Rashid Hospital and an Associate Professor at the Mohammed bin Rashid University of Medicine and Health Sciences, Dubai, UAE. He did his Neuromuscular fellowship and neurology residency at the University of Toronto and received his FRCP from the Royal College of Canada. He is the Vice President of Emirates Neurology Society.



“ Neuromuscular crisis: Dr. Abu Baker Madani ”

- Review list of neurological disease that causes potential rapidly progressive weakness.
 - Clinical symptomatology and subtypes
 - Good and bad prognostic signs
 - Updates in acute treatment
- ”

SCIENTIFIC TALKS

DAY 2, SATURDAY- 9 NOVEMBER 2024

Dr. Fatema Al Omrani

MD, FRCPC

Dr. Fatema Juma Mohammed Al-Amrani is a Pediatric Neurology Consultant affiliated with the Child Neurology Unit at the Child Health Department in Sultan Qaboos University Hospital (SQUH), Muscat, Oman. Dr. Al-Amrani completed her M.D. degree in 2009 from Sultan Qaboos University and Pediatric Neurology Residency at McGill University in Montreal, Canada (2013-2018). Then she pursued a Fellowship in Pediatric Neuromuscular Disorders from the renowned SickKids Hospital at the University of Toronto in 2020.



Approach to floppy infant: Dr. Fatema Al Omrani

Hypotonia is a condition that presents as "floppiness" in infants. It can result from a wide range of neurological and non-neurological disorders, requiring a comprehensive approach for diagnosis and management. Evaluating a floppy infant involves distinguishing between central and peripheral causes of hypotonia, which can be challenging.

Key steps in the approach include:

1. History and Physical Examination: A thorough history, including prenatal and perinatal details, helps identify risk factors and underlying causes. Physical examination assesses muscle tone, strength, reflexes, and developmental milestones.
2. Neurological Evaluation: This helps differentiate central hypotonia (caused by a lesion in the brain or spinal cord) from peripheral hypotonia (caused by a lesion in the nerves, neuromuscular junction, or muscles). Central hypotonia is typically associated with developmental delays, while peripheral hypotonia often presents with weakness and reduced reflexes.
3. Investigations: After clinical evaluation, targeted investigations such as neuroimaging, genetic testing, metabolic studies, and electromyography (EMG) may be required to narrow down the diagnosis.
4. Management: Treatment is guided by the underlying cause and may include physical therapy, occupational therapy, and medical interventions. Prompt diagnosis and intervention are critical to optimizing developmental outcomes for floppy infants.

Dr. Mossaed Al Yahya

MD

Dr. Mossaed Al Yahya is a Consultant Neurologist, neuromuscular and neuro-oncology specialist at King Faisal Specialist Hospital and Research Center. He obtained his MD degree from King Saud University in the Kingdom of Saudi Arabia in 2013 and Neurology residency and Neuromuscular fellowship degrees at Case Western Reserve University in Cleveland as well as another fellowship in Neuro-oncology at the University of Virginia.



Modern therapies of myasthenia gravis: Dr. Mossaed Al Yahya

Myasthenia gravis is an autoimmune neuromuscular disorder that affects neuromuscular junction. It results in fatigable weakness and can affect the ocular, bulbar and limb muscles. Therapies for myasthenia gravis have evolved and recently new medications were approved that target inhibition of complement system and the IgG receptor FcRn. In this lecture, the modern therapies of myasthenia gravis will be discussed.

SCIENTIFIC TALKS

DAY 2, SATURDAY- 9 NOVEMBER 2024

Dr. Ashraf El Mitwalli

MSc., MD

Dr. Ashraf El Mitwalli received Master of Science degree in Neurology and Psychological Medicine from Mansoura School of Medicine, Egypt in 1996. He did fellowship at the University of Texas at Houston at the Stroke program of Memorial Hermann Hospital to complete the clinical part of Neurology medical doctorate from 1999 to 2001 under the supervision of Dr. Andrei Alexandrov and Prof. James Grotta. He worked as Senior Consultant, Professor of Neurology and the Head of the Cerebrovascular team at the University of Mansoura, Neurology Department, Egypt. He is currently Senior Consultant Neurologist at Khoula Hospital, Muscat, Oman.



Stroke in young adults and children: Dr. Ashraf El Mitwalli

Stroke in young adults remains a growing problem worldwide. Young adults are a heterogeneous group of patients whose stroke etiology profile is much different than older stroke patients. Such individuals require a careful clinical evaluation to better understand the stroke mechanism and thus optimize the secondary stroke prevention plan. A technique of evaluation from the 'heart to head' provides a framework for the clinical approach to these unique patients. Pediatric stroke is a rare entity. It is often diagnosed with significant delay due to the subtlety of signs and symptoms, therefore, are frequently undiagnosed or misdiagnosed. Clinicians should be familiar with risk factors for pediatric stroke and appropriate prevention strategies as well as the acute management in neonates and children. Thrombolytic therapy and mechanical thrombectomy are mainly conducted on a case-by-case basis.

Prof. Arunodaya Gujjar

MBBS, DM, FRCP

Prof. Arunodaya R Gujjar is currently a Professor of Neurology at the Sultan Qaboos University Muscat. His areas of interest include Neurocritical Care, Stroke, Electrophysiology, Wilson disease and TeleStroke. He completed his training in Neurology from the National Institute of Neurosciences at India (1990) and Fellowship in Neurocritical Care from the Washington University Medical School, St Louis, USA (1997). In the recent past, his team was awarded national funding for developing TeleStroke in Oman



Approach to ischemic strokes due to multiple mechanisms: Prof. Arunodaya Gujjar

Ischemic stroke (IS) is a heterogeneous condition with varied mechanisms. Some patients have more than one stroke mechanism coexisting, irrespective of the mechanism of the incident stroke. This presentation attempts to describe its prevalence, clinical implications, approach to management and possible preventive measures.

SCIENTIFIC TALKS

DAY 2, SATURDAY- 9 NOVEMBER 2024

Dr. Ahmed Al Azri

MD, B.Sc., M.Sc., MRCSI, FRCSC(C) Neurosurgery

Dr. Ahmed Al Azri is a Neurosurgeon, Consultant & Head of Department of Neurosurgery at Khoula Hospital. He is an affiliated ENT Program Trainer at OMSB. He graduated from the Sultan Qaboos University in 2005, completed his MCCEE in Canada, MRCSI in Ireland, ECFMG in USA, MSc from McGill University in Canada, and FRCSC – Neurosurgery in Canada in 2017. He completed a course on Preparation of Leaders in Managing Healthcare Institutions in Oman in 2024. He received the Award of Excellence from the Khoula Hospital, Ministry of Health.



Current treatment of non-traumatic SAH: Dr. Ahmed Al Azri

Aneurysmal subarachnoid hemorrhage is a significant global public health threat and a severely morbid and often deadly condition. The recommendations present an evidence based approach to preventing, diagnosing, and managing patients with aneurysmal subarachnoid hemorrhage, with the intent to improve quality of care and align with patients' and their families' and caregivers' interests. The recommendations are based on the current published data for the management of aneurysmal subarachnoid hemorrhage.

Dr. Caline El Jadam

MD, DFMS

Dr. Caline Jadam is a Consultant Neurologist at American Center for Psychiatry and Neurology, Abu Dhabi. She graduated as a neurologist in 2014 from Saint Joseph University / Hôtel Dieu de France, Lebanon and holds a fellowship in critical care neurology from Pitié-Salpêtrière hospital in Paris, France. She also completed a Fellowship in Neurophysiology and Epilepsy UPMC-Sorbonne University, Paris France. Dr Caline holds academic and teaching positions as an assistant professor in Balamand University, Faculty of Medicine, Lebanon.



Management of raised ICP: Dr. Caline El Jadam

The talk will discuss management of raised intracranial pressure, and will highlight detection and diagnosis, as well as etiologies and medical management and treatment.

SCIENTIFIC TALKS

DAY 2, SATURDAY- 9 NOVEMBER 2024

Dr. Mahmood Al Hinai
MD, FRCPI

Dr. Mahmood AL-Hinai, Consultant Adult Neurologist and Movement Disorder at Khoula Hospital in Muscat, Oman. He is the Deputy Head of Neurology Department at Khoula Hospital and is General Secretary at the Oman Neurology Society. Graduating from Sultan Qaboos University Medical School, he pursued his residency through the Oman Medical Specialty Board (OMSB), Specialty certificate from The Arab Board of Health Specialization (ABHS) and Membership of the Royal College of Physicians of Ireland (MRCPI). He completed a fellowship in general neurology at the Royal College of Physicians of Ireland. He is a member International Parkinson and Movement Disorder Society.



Approach to shaky hands: Dr. Mahmood Al Hinai

Tremor is defined as an involuntary, rhythmic, and oscillatory movement of a body. Tremor is the most common of all movement disorders. The most common distinction is based on the activating conditions (ie, at rest versus action), but I will address in my talk a new classification and etiological scheme which has been proposed by the International Parkinson and Movement Disorder Society. We will review recent research highlighting the neurophysiological mechanisms underlying various types of tremors, including essential tremor and Parkinsonian tremor. We will touch on innovative treatment options, including pharmacological therapies, deep brain stimulation, and emerging non-invasive techniques such as focused ultrasound. Attendees will gain insights into the evolving landscape of tremor management, aiming to improve patient outcomes through structured treatment approaches.

Dr. Erik Krause
MD, ABPN

Dr. Erik Krause is a neurologist with specialization in Movement disorders. He trained in Neurology at Saint Louis University and for Movement disorder fellowship from University of Texas at Houston McGovern Medical School. His areas of interest include Parkinson's disease, tremors, dystonia, botulinum toxin therapy, and deep brain stimulation programming. In 2019, he became a faculty member of the University of Texas Dell Medical School in Austin, TX.



DBS for movements disorders: Dr. Erik Krause

This presentation will be a basic overview discussing deep brain stimulation (DBS) for common movement disorders. DBS is standard of care therapy used most often for advanced essential tremor, dystonia, and Parkinson's disease. There is well established evidence supporting its use which will be reviewed during this talk. Since its adoption into practice in the 1990's, it has undergone innovative changes expanding surgical techniques and programming options. The goal of this presentation is to review the history and background of DBS, but also provide real world clinical applications when approaching potential candidates for this treatment option. This includes identifying the correct candidate, knowledge of the surgery, and postoperative DBS programming for the general neurologist.

SCIENTIFIC TALKS

DAY 2, SATURDAY- 9 NOVEMBER 2024

Dr. Wejdan Hakami

MD, SBP, CABP, JBP, SBPN

Dr. Wejdan Hakami is a Consultant in Pediatrics and Pediatric neurology, with a specialization in Pediatric Movement Disorders. She is the head of Pediatric Neurology Division at Prince Sultan Military Medical City in Riyadh, Saudi Arabia. Dr. Hakami completed a Pediatric Movement Disorders Fellowship at Phoenix Children's Hospital in the United States. Her interests primarily focus on genetic and autoimmune movement disorders, as well as those associated with neurodegenerative and metabolic conditions.



Phenomenology of Movements Disorders in Children: Dr. Wejdan Hakami

This presentation explores the phenomenology of pediatric movement disorders, highlighting the critical need to clarify specific patterns to enhance diagnostic accuracy. Recognizing these patterns is vital for distinguishing between developmental and neurological disorders, thereby preventing unnecessary or inappropriate treatments, reducing the risk of harm, and improving management outcomes. By identifying distinct movement disorder patterns, we promote early detection especially of treatable conditions enabling timely interventions that can significantly improve outcomes and quality of life for affected children. Furthermore, understanding the complex interplay of neurological and non neurological features, along with variable phenotype-genotype correlations, is essential for comprehensive understanding and effective management. Key topics addressed will include disentangling phenomenology concerning temporal patterns, identifying causes of acute or subacute onset cases, and employing a stepwise approach for chronic and complex movement disorders.

SYMPOSIUM TALKS

DAY 1, FRIDAY- 8 NOVEMBER 2024

Pfizer Symposium

Moderator: Dr. Ahmed Al Qassabi

Speaker: Dr. Taoufik Alsaadi (UAE)

Chief Medical Officer, Chair of the Neurology Department, American Center for Psychiatry and Neurology (ACPN) Abu Dhabi, UAE. Dr. Alsaadi is currently the President of the Emirati League against epilepsy and the Chair of the ILAE Commission for Epilepsy in the Elderly. He serves as a member of the Guideline Development Group (GDG) for the WHO. He also serves on the Editorial Board for the BMC Journal of Neurology and Journal of Neurosciences. He has authored and co-authored more than 85 papers and book chapters and has been peer reviewed for more than 15 scientific journals.



How can we harness Rimegepant in clinical practice today and into the future?

Novartis Symposium

Moderator: Dr. Abdullah Al Asmi

Speaker: Dr Iman Al Lawati (Oman)

Dr. Lawati is a consultant neurologist and multiple sclerosis (MS) specialist at Khoula Hospital, where she oversees the MS care unit. She has authored several publications in her field and has participated as an investigator in numerous clinical trials for MS in the UK. Her primary research interest focuses on pregnancy and lactation among MS patients.



Pioneering Precision with Kesimpta: The first and only self-administered anti-CD20 therapy in MS

Novartis Symposium

Speaker: Dr Nabil Al Macki (Oman)

Dr. Nabil Al Macki is a senior consultant pediatric neurologist. He obtained his medical degree from Sultan Qaboos University and later completed the pediatric neurology residency program at McGill University 2004- 2009.

Dr. Nabil proceeded his career with a fellowship in pediatric neurophysiology.

He has special interests in intractable epilepsies, neurogenetic and neurometabolic disorders. Dr. Nabil was a member in an international commission on medical therapy from the International League Against Epilepsy (ILAE) Task force for dietary therapy. He also has many publications in international journals and presented at national and international conferences.



Signs of SMA

SYMPOSIUM TALKS

DAY 1, FRIDAY- 8 NOVEMBER 2024

AstraZeneca Symposium

Moderator: Dr. Abdullah Al-Salti

Speaker: Dr. Areej Bushnag (KSA)

Dr. Areej Bushnag is a highly experienced neurologist based in Jeddah, Saudi Arabia. With over a decade of clinical experience, she currently serves as a Consultant Neurologist at King Faisal Specialist Hospital and Research Center. She has previously worked at the International Medical Center and King Abdullah Medical Complex. Dr. Bushnag earned her medical degree from King Abdulaziz University, followed by specialized fellowships in Intraoperative Neurophysiological Monitoring and Neuromuscular Disease and Neurophysiology at the University of British Columbia in Canada. She holds certifications from the American Board of Electrodiagnostic Medicine and the Canadian Society of Clinical Neurophysiologists. Her research has been presented at major international conferences, and she has held leadership roles such as Chairman of the Neurology Department. Dr. Bushnag is an active member of several professional organizations, including the American Academy of Neurology and the Saudi Council of Neurology.



Focus on timing on Myasthenia Gravis Management

DAY 2, SATURDAY- 9 NOVEMBER 2024

Pfizer Symposium

Moderator: Dr. Ali Al Balushi

Speaker: Dr. Deeb Kayed (UAE)

He is an Assistant Professor at the Mohammed Bin Rashid University (MBRU) of medicine & His practice is at The Integrated Rheumatology & Arthritis Centre in Dubai Health Care City. Dr. Deeb is an Independent Doctor, Consultant Neurologist, at The Mediclinic City Hospital Dubai in Dubai Health Care City. Dr Kayed's primary interest is in the management of patients with headaches, in particular migraine.



A single medication to both treat and prevent migraine: What is the evidence?

Merck Symposium

Moderator: Dr. Abdullah Al Asmi

Speaker: Dr Iman Lawati (Oman)

Dr. Lawati is a consultant neurologist and multiple sclerosis (MS) specialist at Khoula Hospital, where she oversees the MS care unit. She has authored several publications in her field and has participated as an investigator in numerous clinical trials for MS in the UK. Her primary research interest focuses on pregnancy and lactation among MS patients.



Optimizing Treatment Approach for RRMS Patients

SYMPOSIUM TALKS

DAY 2, SATURDAY- 9 NOVEMBER 2024

Biogen Symposium

Speaker: Dr. Areej Bushnag (KSA)

Dr. Areej Bushnag is a highly experienced neurologist based in Jeddah, Saudi Arabia. With over a decade of clinical experience, she currently serves as a Consultant Neurologist at King Faisal Specialist Hospital and Research Center. She has previously worked at the International Medical Center and King Abdullah Medical Complex. Dr. Bushnag earned her medical degree from King Abdulaziz University, followed by specialized fellowships in Intraoperative Neurophysiological Monitoring and Neuromuscular Disease and Neurophysiology at the University of British Columbia in Canada. She holds certifications from the American Board of Electrodiagnostic Medicine and the Canadian Society of Clinical Neurophysiologists. Her research has been presented at major international conferences, and she has held leadership roles such as Chairman of the Neurology Department. Dr. Bushnag is an active member of several professional organizations, including the American Academy of Neurology and the Saudi Council of Neurology.



“ When Improvement is Possible in Teens and Adults with SMA ”

Roche Symposium

Moderator: Dr Abdullah Al Asmi

Speaker: Dr Raed Al Roughani (Kuwait)

Dr Raed completed his neurology residency at the University of British Columbia and subsequently obtained the neurology certification from the Royal College of Physicians and Surgeons (Canada). He completed a fellowship in Multiple Sclerosis at the University of British Columbia. He is actively involved in research and he authored and co-authored more than 200 publications. Dr Raed was awarded the National Prize for scientific production in the field of medical science in 2017 and the best researcher award by Amiri Hospital in 2018. He is a founding member and the Secretary General of MENACTRIMS. He sits on the executive boards of various scientific associations, steering committees and advisory boards, mainly in the field of MS.



“ Ocrevus: A decade of preventing disability ”

WORKSHOPS

DAY 1, FRIDAY- 8 NOVEMBER 2024

Dr. Haifa Al Abri

MD, ABPN

Completed training of adult neurology residency at Case western Reserve university at Cleveland OH 2016 and completed the American board of psychiatry and neurology (ABPN) certification. Completed fellowship in neurophysiology and epilepsy in 2018 at case western and reserve university at Cleveland Ohio. Currently senior consultant neurologist at sultan Qaboos university hospital (SQUH). Running the epilepsy monitoring unit at SQUH. Interested in management of medical refractory epilepsy and epilepsy surgery evaluation and management. Highly involved in clinical teaching of medical students and residents. Currently the secretary of the Oman epilepsy society and Oman league against epilepsy



Dr. Wafaa Al Shehhi

MBBS, PN-SB, CSCN (EEG Diploma)

Dr. Wafaa is a Consultant, Child Neurologist, epileptologist and Electroencephalographer. She did her fellowship in pediatric epilepsy and EEG at the Hospital for Sick Children, University of Toronto, Canada. She is a member of the Pediatric Commission, ILAE, representative of ILAE- YES (Youth section), and the Vice president, Oman Epilepsy Society.



Seizure Recognition and Semiology: Dr. Haifa Al Abri & Dr. Wafaa Al Shehhi

Paroxysmal events are events that affect a person's awareness, sensation or motor function. The events can be classified as of neurological aetiology, cardiogenic or psychogenic. And under each etiology, there are different classifications. The workshop aims to show videos of different paroxysmal events of both Pediatric and adult population and help the audience to classify them accordingly.

Dr. Buthaina Sabt

MD, FRCS Glasgow

Practicing General ophthalmology and Neuroophthalmology at the Sultan Qaboos university Hospital. Senior Clinical Lecturer, College of Medicine & Health Sciences, Sultan Qaboos University. Muscat, Oman. Faculty and Programme Evaluation Committee member, Ophthalmology Residency Program, Oman Medical Specialty Board, Muscat, Oman M.B, B.Ch, BAO Royal College of surgeons of Ireland, Clinical Fellowship in Neuroophthalmology from Royal Victoria eye and ear Hospital, Dublin, Ireland.



Neuro ophthalmic emergencies you cannot afford to miss: Dr. Buthaina Sabt

Neuro-ophthalmological emergency disorders usually occur with symptoms of visual loss, diplopia, ocular motility impairment and anisocoria.

The workshop will cover common neuro ophthalmic emergency disorders and highlight the importance of early diagnosis to prevent death and blindness.

WORKSHOPS

DAY 2, SATURDAY- 9 NOVEMBER 2024

Dr. Iman Al Lawati

MD, MRCP UK

Dr. Lawati is a consultant neurologist and multiple sclerosis (MS) specialist at Khoula Hospital, where she oversees the MS care unit. She has authored several publications in her field and has participated as an investigator in numerous clinical trials for MS in the UK. Her primary research interest focuses on pregnancy and lactation among MS patients.



Dr. Khalsa Al Ramadhani

MD, DABR (NR), FRCP(C), FRCR(UK)

Dr. Khalsa Al Ramadhani is a neuroradiology consultant and the Head of the Department of Diagnostic and Interventional Services at Khoula Hospital in Muscat, Oman. She serves as the neuroradiology rotation supervisor for radiology residents and is the Deputy Chair of the Examination Committee for the Radiology Program at the Oman Medical Specialty Board. Additionally, Dr. Al Ramadhani is a member of the brain death task force, epilepsy surgery task force and the National Radiology Technical Committee in Oman.



Dr. Al Ramadhani has presented at national and international conferences and has contributed to various publications in radiology and neuroradiology. She plays a significant role in training residents from radiology, ENT, and ophthalmology at the Oman Medical Specialty Board and is a member of several radiology associations, including the RSNA, ASNR, ESNR and ARRS.

Mimics of Inflammatory Myelopathy: Dr. Iman Al Lawati & Dr. Khalsa Al Ramadhani

This workshop will focus on the mimics of inflammatory myelopathy, a challenging area that often requires careful consideration of various differential diagnoses. The session will cover a series of clinical case presentations highlighting diverse scenarios that can easily be mistaken for inflammatory myelopathy. Our Neuroradiologist will share invaluable tips and pearls regarding the interpretation of imaging MRI spine. This segment will emphasize key radiological features that can aid in distinguishing between inflammatory myelopathy and its mimics, enhancing your diagnostic acumen.

Dr. Ali Al Balushi

MD, ABPN

Dr. Ali K. Al Balushi is a consultant, vascular & interventional neurologist and currently head of department of neurology and stroke unit at Khoula Hospital, Oman. He obtained his medical degree from Sultan Qaboos University and completed neurology residency at St Louis University School of Medicine. He then completed fellowship in vascular neurology from Icahn School of Medicine at Mount Sinai and another fellowship in endovascular neurosurgery from Weill Cornell School of Medicine. He is board certified in Neurology and Vascular Neurology by the American Board of Psychiatry and Neurology. He serves as the associate program director for Oman Medical Specialty Board Neurology residency program. Dr. Ali is the Chairman of the Scientific Committee of the 4th Oman Neurology Conference.



Dr. Achint Krishna

MD, DM Neurology

Dr Achint Krishna graduated from MBBS in 2011 with distinction, following which he pursued MD in Internal Medicine. During the course of which he did his doctoral thesis in Asian Modification of Metabolic Syndrome. Following his graduation in 2014, he practiced Internal Medicine for 2 years. He pursued Residency in Neurology from 2016- 2019 and graduated Top of the class in the University. During the course he did his research on RESTLESS LEG SYNDROME in India. He also did multiple Paper presentations On Nonaka Myopathy. He worked In Aster India from 2019-2021. He has been a part of Aster Oman since 2021.



Stroke cases: Dr. Ali Al Balushi & Dr. Achint Krishna

Stroke is the second leading cause of death and the main leading cause of disability worldwide. The emergency evaluation and treatment of both ischemic and hemorrhagic strokes have evolved significantly over the past years. In this interactive workshop, different stroke cases will be presented and discussed with the audience with emphasis on the hyperacute management. This will be presented along with take-home messages after each case discussion.

